Howard Pratt
Psychiatry · Miami, FLNPI 1033526785
Payments from drug & device makers
Across 234 payments — averaging $57.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$7K
- Neurocrine Biosciences, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$2K
- AbbVie$772
- Johnson & Johnson$496
- Alkermes, Inc.$369
- plus $923 from 11 others
What the payments were for
- Consulting fees$5,52041%
- Travel & lodging$7976%
- Food & beverage$7,02552%
- Education$711%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 21 | $7,109 |
| Neurocrine Biosciences, Inc. | 49 | $2,145 |
| Teva Pharmaceuticals USA, Inc. | 33 | $1,601 |
| AbbVie(2 entities) | 50 | $772 |
| Johnson & Johnson | 25 | $496 |
| Alkermes, Inc. | 17 | $369 |
| Indivior Inc. | 12 | $267 |
| Otsuka America Pharmaceutical, Inc. | 11 | $215 |
| Sunovion Pharmaceuticals Inc. | 7 | $139 |
| Luye Pharma (USA) Ltd. | 1 | $130 |
| Janssen Scientific Affairs, LLC | 1 | $51 |
| Tris Pharma Inc | 2 | $28 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Shire North American Group Inc | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Vertical Pharmaceuticals, LLC | 1 | $16 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$1,180
- Austedo XR$639
- UZEDY$363
- COBENFY$286
- AUSTEDO$135
- ERZOFRI EXTENDED-RELEASE$130
How this compares
$13,414 in reported general payments places this provider in the 85th percentile of 2,059 psychiatry providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate | 71 | $1,118 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 14 | $850 |
| Haloperidol Decanoate | 16 | $761 |
| Fluvoxamine Maleate | 14 | $709 |
| Aripiprazole | 15 | $637 |
| Divalproex Sodium | 25 | $509 |
| Olanzapine | 31 | $499 |
| Benztropine Mesylate | 48 | $411 |
| Risperidone | 45 | $393 |
| Haloperidol | 20 | $385 |
| Mirtazapine | 15 | $382 |
| Hydroxyzine Hcl | 25 | $322 |
| Trazodone Hcl | 54 | $250 |
| Clonazepam | 36 | $176 |
| Bupropion XlBupropion Hcl | 22 | $175 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Miami
- Silvia Silva-DulucMiami$11.7M
- Patricia JunqueraMiami$10.8M
- Evelio SosaMiami$6.9M
- Mario CuervoMiami$6.7M
- Emelina ArochaMiami$4.9M
- Maria RodilMiami$4.5M
- Marc AgroninMiami$4M
- Nancy Navarro-GonzalezMiami$2.6M
- Francisco RicartMiami$2.6M
- Durim BozhdarajMiami$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.